Stock APPH APONTIS PHARMA AG
Add to a list
To use this feature you must be a member
Log inSign up

News Apontis Pharma AG Deutsche Boerse AG

Equities

APPH

DE000A3CMGM5

Real-time Estimate Tradegate
Other stock markets
 11:30:11 29/04/2024 am IST 		5-day change 1st Jan Change
8.28 EUR +3.76% Intraday chart for Apontis Pharma AG +3.91% +70.51%
05/04 Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications MT
28/03 Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications
MT
APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast
EQ
APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications
EQ
Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023
CI
APONTIS PHARMA expects profitable growth again in 2024
EQ
Apontis Pharma : Earnings Call 2023 Presentation
PU
Transcript : Apontis Pharma AG - Special Call
APONTIS PHARMA successfully completes performance and efficiency improvement program
EQ
APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures for 2023 and new sales and earnings forecast for 2023 published
EQ
Apontis Pharma Provides Earnings Guidance for the Full Year 2023
CI
APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program
EQ
Apontis Pharma AG Reports Earnings Results for the Half Year Ended June 30, 2023
CI
APONTIS PHARMA confirms preliminary figures – H1 2023 sales and earnings decline
EQ
AstraZeneca Cancels Lung Disease Drug Co-promotion Deal With Apontis Pharma
MT
APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024
EQ
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 – Preparation of program to increase operating performance and efficiency launched
EQ
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026
EQ
Apontis Pharma CEO Steps Down; New Chief to Start September
MT
APONTIS PHARMA: CEO Karlheinz Gast resigns for personal reasons - Bruno Wohlschlegel takes over as successor
EQ
Apontis Pharma AG Announces Executive Changes
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APPH Stock
  4. APPH Stock
  5. News Apontis Pharma AG